Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) Research & Development: ¥20.6 Mil (TTM As of Mar. 2026)


SHSE:603168 Zhejiang Shapuaisi Pharmaceutical Co Ltd SHSE:603168
37 GF Score
Price ¥4.97
GF Value ¥8.60
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zhejiang Shapuaisi Pharmaceutical Co Research & Development?

Zhejiang Shapuaisi Pharmaceutical Co SHSE:603168 37 Research & Development is ¥20.6 Mil as of Mar. 2026. GuruFocus rates SHSE:603168 with a GF Score™ of 37/100 and a GF Value™ of ¥8.60 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Zhejiang Shapuaisi Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was ¥4.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥20.6 Mil.

Zhejiang Shapuaisi Pharmaceutical Co  (SHSE:603168) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zhejiang Shapuaisi Pharmaceutical Co Research & Development Related Terms

Zhejiang Shapuaisi Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Zhejiang Shapuaisi Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Shapuaisi Pharmaceutical Co Research & Development Chart

Zhejiang Shapuaisi Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 102.21 59.62 64.45 57.58 25.20

Zhejiang Shapuaisi Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.24 2.53 3.09 10.34 4.64
SHSE:603168
37GF Score
Zhejiang Shapuaisi Pharmaceutical Co Ltd SHSE:603168
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Shapuaisi Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥20.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥20.6 Mil mean?
Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) has a Research & Development of ¥20.6 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Zhejiang Shapuaisi Pharmaceutical Co and its competitors.
Is Zhejiang Shapuaisi Pharmaceutical Co's Research & Development too high?
Zhejiang Shapuaisi Pharmaceutical Co's current Research & Development is ¥20.6 Mil. Overall, Zhejiang Shapuaisi Pharmaceutical Co has a GF Score™ of 37/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Shapuaisi Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Zhejiang Shapuaisi Pharmaceutical Co's Research & Development of ¥20.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zhejiang Shapuaisi Pharmaceutical Co and its competitors. Zhejiang Shapuaisi Pharmaceutical Co's current Research & Development is ¥20.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Shapuaisi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥8.60, compared to a current price of ¥4.97 — trading 42.2% below its estimated fair value. The current Research & Development is ¥20.6 Mil. Zhejiang Shapuaisi Pharmaceutical Co's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168), the current Research & Development is ¥20.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥4.97 is trading 42.2% below its estimated GF Value™ of ¥8.60. GuruFocus considers Zhejiang Shapuaisi Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:603168:

  • Research & Development: ¥20.6 Mil
  • GF Value™: ¥8.60 vs. price of ¥4.97 (42.2% below fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Shapuaisi Pharmaceutical Co Business Description

Address No. 1588 Xinming Road, Economic Development Zone, Zhejiang Province, Pinghu, CHN, 314200
Zhejiang Shapuaisi Pharmaceutical Co Ltd is a China based pharmaceutical company. It is engaged in drug research and development, production and operation. The product portfolio of the company includes oral solutions, eye drops, tablets, hard capsules, suppositories, granules, raw materials dosage forms such as medicines, rinsing agent and mixture, and others. The company operates pharmaceutical manufacturing companies, pharmaceutical sales company, pharmaceutical retail company and pharmaceutical research institute. The products offered by the company are sold in China and are also exported to the other countries.
37GF Score

Get the complete analysis for SHSE:603168

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.97
Price
¥8.60
GF Value